Top U.S. doctors offer updated flu and COVID vaccine recommendations, aiming to ease confusion

• A recent Annenberg survey reveals a significant trust gap in U.S. healthcare, with 87% of Americans trusting their own doctors while confidence in the CDC, FDA, and NIH has dropped sharply. • This trend persists across various public health scenarios, including drug safety communications, food product recalls, and outbreak advisories.

• A Public Health Alerts report has identified over 6,000 cases of cyclosporiasis in Michigan through July 22, 2026, linked to contaminated iceberg lettuce. • This event marks the largest known outbreak of the diarrheal illness in U.S. history, highlighting significant risks in the produce supply chain.

• Researchers have discovered that a protein linked to cancer, specifically the BRAF pathway, may play a critical role in the development of chronic nerve pain. • The study suggests that existing cancer drugs targeting this biological pathway could potentially be repurposed to treat neuropathic pain by addressing pain amplification at its source.

• Public health debates have intensified following two "measles-associated" deaths in Pennsylvania and the FDA's approval of updated COVID-19 vaccines. • Critics are questioning the lack of direct randomized human efficacy trials for the new vaccine formulations and the transparency of the approval process.

• Health experts are warning of a potentially severe 2026 flu season in the US, driven primarily by the H3N2 strain. • A new flu vaccine has been developed specifically for adults over 50 to provide enhanced protection against the virus.

• A retrospective review of FDA novel drug approvals from 2016 through 2024 reveals a trend of approvals being supported by a decreasing number of completed clinical studies. • Researchers analyzed FDA public records and the ClinicalTrials.gov database to evaluate trial counts, funding sources, and the timing of public result reporting.

• The FDA has approved updated COVID-19 vaccines specifically designed to target the XFG variant for the 2026-2027 season. • The new shots are rolling out to provide maximum protection against the evolving strain, with guidance available on eligibility and optimal timing for administration.

• A new study reveals that nearly 70% of new drugs approved by the FDA between 2016 and 2024 were granted approval based on a single clinical trial. • Researchers analyzed FDA records and the ClinicalTrials.gov database to track the number of supporting studies, funding sources, and the speed of public result releases.

• The FDA approved a first-of-its-kind oral treatment from Roivant and Priovant Therapeutics for a rare disease affecting skin and muscles. • Following the announcement on Thursday, Roivant shares saw a 2% increase, closing at $37.58 in afternoon trading.

• The White House is finalizing drug pricing agreements with pharmaceutical companies Bayer, Takeda, and CSL Behring. • These deals are part of a broader initiative by the U.S. government to secure more affordable medication costs through direct negotiations with drugmakers.

• NanoViricides, Inc. (NASDAQ:NNVC) has announced an update to its Measles Drug Treatment Program, introducing a new potential treatment candidate called NV-387. • The development of NV-387 comes in response to a global rise in measles cases, aiming to provide a viable therapeutic option for outbreaks.